StockNews.com Begins Coverage on Check-Cap (NASDAQ:CHEK)

StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note released on Sunday morning. The brokerage issued a sell rating on the medical research company’s stock.

Check-Cap Stock Down 3.3 %

Check-Cap stock opened at $0.75 on Friday. The stock has a market cap of $4.36 million, a P/E ratio of -0.25 and a beta of 0.19. Check-Cap has a twelve month low of $0.56 and a twelve month high of $3.45. The company’s 50-day moving average price is $1.05 and its two-hundred day moving average price is $1.18.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.